The oncogene KRAS point mutation was reported by many literatures to be the major molecular event in pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma, [28–31] as well as pancreatic cystic lesions. Here, KRAS is linked to cholangiocarcinoma.